Canopy Growth Corp vs 8x8 Inc — how do they compare? Canopy Growth Corp trades at $1 (market cap $399.40M), while 8x8 Inc trades at $2.16 (market cap $323.54M). The key difference: Canopy Growth Corp is the larger of the two by market cap, and 8x8 Inc is trading nearer its 52-week high, Canopy Growth Corp nearer its low. Which is the better fit depends on your goals.
| CGC | EGHT | |
|---|---|---|
Market Cap | $399.40M | $323.54M |
Sector | Health | Technology |
52-Week High | $1.92 | $2.76 |
52-Week Low | $0.86 | $1.59 |
Enterprise Value | $356.90M | $590.46M |
Signals from Pluang's Aura AI — not financial advice
CGC trades at $0.9701, up 4.07% in 24 hours, with a neutral technical signal and mixed analyst ratings (9 buy, 11 hold, 7 sell). The company reported Q1 2027 revenue growth of 13% year-over-year but continues to post net losses, with a negative net income margin of -92.38% in 2026. Cash flow trends show improving operational efficiency, though negative operating cash flow persists. Recent news highlights progress on profitability measures and anticipation of U.S. cannabis rescheduling decisions.
The outlook remains cautious due to persistent unprofitability and regulatory uncertainties, but cost-cutting and revenue growth offer potential upside. Key risks include high debt, competitive pressures, and delayed federal cannabis reforms. Analysts are divided, reflecting the stock's high-risk, high-reward profile amid ongoing turnaround efforts.
EGHT trades at $2.30, up 1.1% today, with a bullish technical signal from moving averages. The company shows strong revenue growth, with five consecutive quarters of year-over-year increases, and has beaten EPS estimates in recent quarters. Recent news highlights the launch of a new partner program and expansion of AI capabilities across its platform. However, the stock carries a high P/E ratio of 74.67, and the company reported a net loss of $27.21 million for 2025.
The outlook is cautiously optimistic, with analyst consensus pointing to significant upside with a $3.13 price target. Key opportunities include sustained revenue growth and AI-driven product expansion, while risks involve high valuation, debt levels, and the challenge of achieving consistent profitability. Institutional sentiment is mixed but leans positive.
Trailing returns across standard periods
Latest headlines on both assets
Canopy Growth, headquartered in Smiths Falls, Canada, cultivates and sells medicinal and recreational cannabis, and hemp, through a portfolio of brands that include Tweed, Spectrum Therapeutics, and CraftGrow. Although it primarily operates in Canada, Canopy has distribution and production licenses in more than a dozen countries to drive expansion in global medical cannabis and also holds an option to acquire Acreage Holdings upon U.S. federal cannabis legalization.
Read more on CGC →8x8 is a provider of integrated cloud communications and contact center solutions. Its platform combines voice, video, chat, and contact center functionality into a single application to help businesses collaborate.
Read more on EGHT →